New

Global ETF Survey 2026 Available: How 620 Professionals Select ETFs. Access the Report →

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

Access the report

›ETF Issuers›Invesco›PBE

PBE

Invesco Dynamic Biotechnology & Genome ETF

Passive ETF Equity Theme: BioTech & Genomics

The PBE Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: Dynamic Biotech & Genome Intellidex Index. The PBE ETF provides physical exposure, so by buying it you actually own parts of all the 30 underlying holdings. This share class generates a stream of income by distributing dividends.

$100.27

+$0.65 (+0.65%) yesterday

2:30 PM 11/11/26 Closed

1D price range

$99.04$100.37

52W price range

$75.50$104.69

YTD Perf.

+22.57%

YTD Flows

Annualized volatility

Fund AuM

€392M

Share class AuM

€392M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

US46137V7872

TER

0.59%

Inception date

6/23/2005

Issuer

Invesco

Benchmark

Dynamic Biotech & Genome Intellidex Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
TMED T. Rowe Price Health Care ETF	+3.17%
IBBQ Invesco Nasdaq Biotechnology ETF	+1.63%
203780 Mirae Asset TIGER NASDAQ BIO ETF	+3.02%
BTEE iShares Nasdaq US Biotechnology UCITS ETF	+1.63%
PINK Simplify Health Care ETF	+1.11%
00678 CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF	+3.98%
IBB iShares Biotechnology ETF	+0.79%
IHE iShares U.S. Pharmaceuticals ETF	+3.56%
PJP Invesco Dynamic Pharmaceuticals ETF	+1.17%
EKG First Trust Nasdaq Lux Digital Health Solutions ETF	-0.19%
GNMX Corgi Genomics & Precision Medicine ETF	-2.12%
HTEC Robo Global Healthcare Technology and Innovation ETF	+0.93%
WDNA WisdomTree BioRevolution UCITS ETF	-1.99%
FBT First Trust NYSE Arca Biotechnology Index Fund ETF	-0.11%
ZUH BMO Equal Weight U.S. Health Care Index ETF	+2.11%

API

PerformanceDec 31, 2025 - Nov 10, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 09/30/26

Healthcare

100.00%

Latest PBE news

No content available for this fund

FAQ about PBE

PBE is a passively managed ETF that invests in the BioTech & Genomics segment.

PBE tracks the Dynamic Biotech & Genome Intellidex TR Index - USD, through a full replication replication method.

PBE carries a total expense ratio (TER) of 0.59%.

PBE was introduced to the market on June 23, 2005.

Invesco Dynamic Biotechnology & Genome ETF, PBE, is provided by Invesco. Learn more about Invesco here.

PBE oversees €392M in assets as of November 10, 2026.

PBE follows a distributing dividend policy, meaning it pays out income to investors. As of November 10, 2026, its 12-month trailing yield was 1.34%.

As of September 30, 2026, PBE has significant geographic allocations in USA and Netherlands.

As of September 30, 2026, PBE focuses largely on Healthcare.

As of September 30, 2026, PBE holds 30 positions in its portfolio, with 62.68% of assets concentrated in its top 15 holdings.

As of September 30, 2026, PBE top three holdings include Natera, Inc., Illumina, Inc. and Biogen, Inc..

The base currency of PBE is USD.

Top 10 holdings

Data as of 09/30/26

Natera, Inc.

6.20%

Illumina, Inc.

6.13%

Biogen, Inc.

5.25%

Gilead Sciences, Inc.

5.19%

Vertex Pharmaceuticals, Inc.

4.84%

Amgen, Inc.

4.79%

Royalty Pharma Plc

4.77%

Regeneron Pharmaceuticals, Inc.

4.57%

Moderna, Inc.

3.43%

Novavax, Inc.

3.16%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

Trackinsight Global ETF Survey 2026: ETFs' Next Act: From Access to Selection. Access the report

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

Invesco Dynamic Biotechnology & Genome ETF

FAQ about PBE

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US